In this SABCS 2025 conference video, Dr. Virginia Kaklamani, Professor of Medicine at UT Health San Antonio and Co-Director of SABCS, discusses key advances shaping contemporary breast cancer care. Highlights include emerging applications of artificial intelligence in breast cancer management, findings from the HER2-CLYMO5 trial supporting chemotherapy de-escalation with tucatinib, and promising phase 3 data evaluating the oral selective estrogen receptor degrader giredestrant.

Dr. Isabel Bedrosian, Professor of Breast Surgical Oncology at MD Anderson Cancer Center, reviews results from the Alliance A11104 trial, which demonstrated that routine preoperative breast MRI did not improve locoregional control or survival in patients with early-stage breast cancer. These findings reinforce evidence-based surgical decision-making and support a more selective approach to preoperative imaging.

Share your thoughts

At ENDO 2025, Dr. Monica Laronda (Lurie Children’s Hospital, Northwestern University) highlighted emerging research investigating how GLP-1 therapies and rising obesity rates may influence puberty onset, menarche timing, and sex-specific disease expression—particularly in adolescents with high BMI or genetic susceptibility. She also discussed environmental and epigenetic drivers of endocrine disruption and underscored the need to consider sex as a biological variable in metabolic research. Dr. Shellsea Portillo (St. Louis University Hospital) presented retrospective data indicating that GLP-1–associated weight loss significantly improved testosterone levels in obese men with type 2 diabetes, suggesting a possible avenue for further exploration as a non-hormonal strategy for managing obesity-related hypogonadism. Together, these insights underscore GLP-1’s emerging but preliminary role in reproductive and metabolic endocrine health.